Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01853228
Recruitment Status : Terminated (EMA/PDCO acknowledged that available results from this study do not support further clinical studies in relapsed/refractory AML paediatric patients.)
First Posted : May 14, 2013
Results First Posted : June 17, 2019
Last Update Posted : June 17, 2019
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:
The purpose of this study is to examine the safety and efficacy of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukemia (AML).

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Phase1 and Phase 2: decitabine Drug: Phase 1: cytarabine Drug: Phase 2: cytarabine Phase 1 Phase 2

Detailed Description:
This is an open-label (identity of assigned study drug will be known) study to evaluate safety, efficacy, and pharmacokinetics (study of what the body does to a drug) of decitabine in sequential administration with cytarabine in children with relapsed or refractory AML. The study will determine the maximum tolerated dose of cytarabine that can be given following decitabine (Phase 1) and the response rate to this combination (Phase 2). Participants may enter a continuation phase of single agent-decitabine infusions for as long as such treatment would be considered beneficial. Serial pharmacokinetic samples will be collected and safety and efficacy will be monitored throughout the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia
Actual Study Start Date : October 22, 2013
Actual Primary Completion Date : August 28, 2017
Actual Study Completion Date : August 28, 2017


Arm Intervention/treatment
Experimental: Decitabine and cytarabine Drug: Phase1 and Phase 2: decitabine
20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)

Drug: Phase 1: cytarabine
1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose

Drug: Phase 2: cytarabine
Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)




Primary Outcome Measures :
  1. Phase 1: Maximum Tolerated Dose (MTD) of Cytarabine [ Time Frame: Cycle 1 (42 days) ]
    The maximum tolerated dose (MTD) for cytarabine was based on the number of participants experiencing a dose-limiting toxicity (DLT) by the end of Cycle 1. A non-hematological DLT was defined as: any Grade >=3 toxicity that persists for greater than (>) 5 days or any Grade 2 toxicity that persists for >7 days and that is intolerable to the participant. A hematological DLT was defined as Grade 4 neutropenia or thrombocytopenia due to a hypoplastic bone marrow at Day 42, in the absence of malignant infiltration. The nominal duration of each cycle was 28 days. However, participants who had not experienced bone marrow recovery at Day 28 were followed up to Day 42. Failure of marrow recovery (improvement to Grade 3) by Day 42 was considered a DLT. The maximum duration of Cycle 1 was therefore 42 days.

  2. Phase 1 and 2: Total Clearance of Decitabine [ Time Frame: Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 minute (min), 0.5 hour, 1 hour, and 2 hour after end of infusion ]
    Total clearance of drug after intravenously administration was calculated as: dose/area under the plasma concentration-time curve.

  3. Phase 1 and 2: Volume of Distribution at Steady-State (Vss) of Decitabine [ Time Frame: Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 min, 0.5 hour, 1 hour, and 2 hour after end of infusion ]
    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.

  4. Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 1 Day 28 [ Time Frame: Cycle 1 (28 days) Day 28 ]
    Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than [<] 1,000/microliter) or thrombocytopenia <100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (>) 1,000/ microliter, platelet count of >100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.

  5. Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 2 Day 28 [ Time Frame: Cycle 2 (28 days) Day 28 ]
    Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than [<] 1,000/microliter) or thrombocytopenia <100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (>) 1,000/ microliter, platelet count of >100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.

  6. Phase 2: Percentage of Participants Who Achieved CR or CRi at End of Study Treatment [ Time Frame: End of study treatment (approximately 3 years) ]
    Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than [<] 1,000/microliter) or thrombocytopenia <100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (>) 1,000/ microliter, platelet count of >100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.


Secondary Outcome Measures :
  1. Phase 1 and 2: Maximum Plasma Concentration (Cmax) of Decitabine [ Time Frame: Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 min, 0.5 hour, 1 hour, and 2 hour after end of infusion ]
    Cmax is the maximum observed plasma concentration of Decitabine.

  2. Phase 1 and 2: Area Under the Plasma Concentration-Time Curve (AUC) of Decitabine [ Time Frame: Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 min, 0.5 hour, 1 hour, and 2 hour after end of infusion ]
    AUC is the area under the plasma concentration-time curve of decitabine.

  3. Phase 2: Duration of Response [ Time Frame: From time of response to relapse, study completion/withdrawal, or death, whichever comes first, for up to approximately 3 years 10 months ]
    Duration of response is defined as weeks from date of first response to date of first relapse or date of death.

  4. Phase 2: Overall Response Rate [ Time Frame: Up to approximately 3 years 10 months ]
    Overall response rate is defined as percentage of participants with complete remission (CR) +complete remission with incomplete blood count recovery (CRi)+partial remission (PR) per IWG Criteria. CRi: morphologic CR with residual neutropenia (less than [<] 1,000/microliter) or thrombocytopenia <100,000/microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (>) 1,000/ microliter platelet count of >100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment. PR: all the same hematologic values of a CR, but with a decrease of >=50% of the percentage of blasts to 5% to 25% in the bone marrow aspirate.

  5. Phase 1 and 2: Overall Survival (OS) [ Time Frame: From enrollment to death or withdrawal, whichever comes first, for up to approximately 3 years 10 months ]
    OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.

  6. Phase 1 and 2: Event-Free Survival [ Time Frame: From enrollment to progression/relapse, death, or withdrawal, whichever comes first, for up to approximately 3 years 10 months ]
    Event free survival is defined as the time from first dose of study drug to relapse from CR, death, or second malignancy for participants who achieved CR. CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (>) 1,000/ microliter platelet count of >100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.

  7. Phase 1 and 2: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Approximately 3 years 10 months ]
    TEAEs are defined as adverse events with onset or worsening on or after date of first dose of study treatment. An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological diagnosis of acute myeloid leukemia (AML) according to the World Health Organization (WHO) classification
  • Diagnosis of AML which has relapsed or is refractory to standard of care and no curative therapy exists
  • Karnofsky or Lansky score of at least 50
  • Must be recovered from acute toxicity of any prior treatment
  • Must have adequate organ function according to protocol-defined criteria
  • Agrees to protocol-defined use of effective contraception
  • Female participants of childbearing potential must have a negative serum or urine pregnancy test at Day 1 of Cycle 1

Exclusion Criteria:

  • Prior treatment with decitabine or azacitidine
  • Acute promyelocytic leukemia (M3 subtype in the French-American-British [FAB] classification system)
  • CNS3 disease
  • acute myeloid leukemia (AML) associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome or Diamond-Blackfan anemia, or bone marrow failure associated with inherited syndromes
  • White blood cell count greater than 40x10^9 cells/liter(L)
  • Known allergies, hypersensitivity, or intolerance to decitabine or cytarabine or their excipients
  • Contraindications to the use of cytarabine per local prescribing information or prior adverse reactions to cytarabine which would prevent further use
  • Currently enrolled in the treatment phase of an interventional investigational study
  • Female who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study drug (however, the period after which it becomes safe to become pregnant after the last dose of treatment is not known)
  • Male who plans to father a child while enrolled in this study or within 3 months after the last dose of study drug
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient or that could prevent, limit, or confound the protocol-specified assessments
  • Any social or medical condition that in the investigator's opinion renders the participant unfit for study participation
  • History of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease
  • History of human immunodeficiency virus (HIV) antibody positive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01853228


Locations
Layout table for location information
Belgium
Gent, Belgium
Denmark
Copenhagen Ø, Denmark
France
Paris, France
Toulouse Cedex 9, France
Vandoeuvre-Lès-Nancy, France
Germany
Essen, Germany
Hamburg, Germany
Hannover, Germany
Stuttgart, Germany
Netherlands
Rotterdam, Netherlands
Spain
Barcelona, Spain
Madrid, Spain
Valencia, Spain
United Kingdom
Birmingham, United Kingdom
Cambridge, United Kingdom
Glasgow, United Kingdom
Sutton, United Kingdom
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Layout table for investigator information
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
  Study Documents (Full-Text)

Documents provided by Janssen Research & Development, LLC:

Layout table for additonal information
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT01853228     History of Changes
Other Study ID Numbers: CR102071
DACOGENAML2004 ( Other Identifier: Janssen Research & Development, LLC )
2013-000390-70 ( EudraCT Number )
First Posted: May 14, 2013    Key Record Dates
Results First Posted: June 17, 2019
Last Update Posted: June 17, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Janssen Research & Development, LLC:
Acute myeloid leukemia
Relapsed or refractory acute myeloid leukemia
Children
Decitabine
DACOGEN
Cytarabine

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Cytarabine
Decitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Enzyme Inhibitors